Literature DB >> 25819327

Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Jason S McLellan1.   

Abstract

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis, but despite decades of research a safe and effective vaccine has remained elusive. The viral fusion glycoprotein (RSV F) plays an obligatory role in the entry process and is the major target of neutralizing antibodies, making it an attractive target for vaccine development. This review will summarize the recently determined structures of RSV F in the prefusion and postfusion conformations and describe the location and properties of neutralizing epitopes on RSV F, including the newly identified prefusion-specific epitopes. The influence of these findings on vaccine development will also be discussed, with a focus on the rational design and optimization of vaccine antigens.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25819327      PMCID： PMC4456247          DOI： 10.1016/j.coviro.2015.03.002

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN： 1879-6257            Impact factor:   7.090


  42 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches.

Authors:  Sheng-Jiun Wu; Albert Schmidt; Eric J Beil; Nicole D Day; Patrick J Branigan; Changbao Liu; Lester L Gutshall; Concepción Palomo; Julie Furze; Geraldine Taylor; José A Melero; Ping Tsui; Alfred M Del Vecchio; Marian Kruszynski
Journal:  J Gen Virol       Date:  2007-10       Impact factor: 3.891

3.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

4.  Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming.

Authors:  Mark J Kwakkenbos; Sean A Diehl; Etsuko Yasuda; Arjen Q Bakker; Caroline M M van Geelen; Michaël V Lukens; Grada M van Bleek; Myra N Widjojoatmodjo; Willy M J M Bogers; Henrik Mei; Andreas Radbruch; Ferenc A Scheeren; Hergen Spits; Tim Beaumont
Journal:  Nat Med       Date:  2009-12-20       Impact factor: 53.440

5.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

6.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

7.  Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.

Authors:  Jason S McLellan; Man Chen; Jung-San Chang; Yongping Yang; Albert Kim; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

8.  Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Authors:  Abdul S Yunus; Trent P Jackson; Katherine Crisafi; Irina Burimski; Nicole R Kilgore; Dorian Zoumplis; Graham P Allaway; Carl T Wild; Karl Salzwedel
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

9.  Structural basis of respiratory syncytial virus neutralization by motavizumab.

Authors:  Jason S McLellan; Man Chen; Albert Kim; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2010-01-24       Impact factor: 15.369

10.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Authors:  Herren Wu; David S Pfarr; Syd Johnson; Yambasu A Brewah; Robert M Woods; Nita K Patel; Wendy I White; James F Young; Peter A Kiener
Journal:  J Mol Biol       Date:  2007-02-20       Impact factor: 5.469
View more
  37 in total

1.  Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Authors:  Normand Blais; Martin Gagné; Yoshitomo Hamuro; Patrick Rheault; Martine Boyer; Ann-Muriel Steff; Guy Baudoux; Vincent Dewar; Josée Demers; Jean-Louis Ruelle; Denis Martin
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Authors:  A Leemans; M De Schryver; W Van der Gucht; A Heykers; I Pintelon; A L Hotard; M L Moore; J A Melero; J S McLellan; B S Graham; L Broadbent; U F Power; G Caljon; P Cos; L Maes; P Delputte
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

3.  Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

Authors:  Jarrod J Mousa; Marion F Sauer; Alexander M Sevy; Jessica A Finn; John T Bates; Gabriela Alvarado; Hannah G King; Leah B Loerinc; Rachel H Fong; Benjamin J Doranz; Bruno E Correia; Oleksandr Kalyuzhniy; Xiaolin Wen; Theodore S Jardetzky; William R Schief; Melanie D Ohi; Jens Meiler; James E Crowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

4.  Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.

Authors:  Xiang Liu; Bo Liang; Joan Ngwuta; Xueqiao Liu; Sonja Surman; Matthias Lingemann; Peter D Kwong; Barney S Graham; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

5.  Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.

Authors:  Linda G Brock; Xiang Liu; Bo Liang; Matthias Lingemann; Xueqiao Liu; Richard Herbert; Ashley D Hackenberg; Ursula J Buchholz; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

6.  RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

Authors:  Pierre-Louis Hervé; Charlotte Deloizy; Delphyne Descamps; Marie-Anne Rameix-Welti; Jenna Fix; Jason S McLellan; Jean-François Eléouët; Sabine Riffault
Journal:  Nanomedicine       Date:  2016-08-20       Impact factor: 5.307

7.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

8.  Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Authors:  Ivy Widjaja; Oliver Wicht; Willem Luytjes; Kees Leenhouts; Peter J M Rottier; Frank J M van Kuppeveld; Bert Jan Haijema; Cornelis A M de Haan
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 9.  A multifaceted approach to RSV vaccination.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Trudy G Morrison; Stefanie N Vogel
Journal:  Hum Vaccin Immunother       Date:  2018-06-19       Impact factor: 3.452

10.  Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.

Authors:  Laura M Stephens; Kathleen A Ross; Kody A Waldstein; Kevin L Legge; Jason S McLellan; Balaji Narasimhan; Steven M Varga
Journal:  J Immunol       Date:  2021-04-07       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.